{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:42:53Z","timestamp":1788298973371,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104198"],"award-info":[{"award-number":["82104198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171479"],"award-info":[{"award-number":["32171479"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2008085MH274"],"award-info":[{"award-number":["2008085MH274"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2108085QH377"],"award-info":[{"award-number":["2108085QH377"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M671916"],"award-info":[{"award-number":["2020M671916"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Enhancer of zeste homolog 2 (EZH2), an enzymatic subunit of PRC2 complex, plays an important role in tumor development and progression through its catalytic and noncatalytic activities. Overexpression or gain-of-function mutations of EZH2 have been significantly associated with tumor cell proliferation of triple-negative breast cancer (TNBC) and diffuse large B-cell lymphoma (DLBCL). As a result, it has gained interest as a potential therapeutic target. The currently available EZH2 inhibitors, such as EPZ6438 and GSK126, are of benefit for clinical using or reached clinical trials. However, certain cancers are resistant to these enzymatic inhibitors due to its noncatalytic or transcriptional activity through modulating nonhistone proteins. Thus, it may be more effective to synergistically degrade EZH2 in addition to enzymatic inhibition. Here, through a rational design and chemical screening, we discovered a new irreversible EZH2 inhibitor, IHMT-337, which covalently bounds to and degrades EZH2 via the E3 ligase CHIP-mediated ubiquitination pathway. Moreover, we revealed that IHMT-337 affects cell cycle progression in TNBC cells through targeting transcriptional regulating of CDK4, a novel PRC2 complex- and enzymatic activity-independent function of EZH2. More significantly, our compound inhibits both DLBCL and TNBC cell proliferation in different preclinical models in vitro and in vivo. Taken together, our findings demonstrate that in addition to enzymatic inhibition, destroying of EZH2 by IHMT-337 could be a promising therapeutic strategy for TNBC and other malignancies that are independent of EZH2 enzymatic activity.<\/jats:p>","DOI":"10.1038\/s41392-022-01240-3","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T01:02:20Z","timestamp":1673830940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies"],"prefix":"10.1038","volume":"8","author":[{"given":"Husheng","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongru","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-2547","authenticated-orcid":false,"given":"Qingsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"1240_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1225237","volume":"337","author":"W Yuan","year":"2012","unstructured":"Yuan, W. et al. Dense chromatin activates Polycomb repressive complex 2 to regulate H3 lysine 27 methylation. Science 337, 971\u2013975 (2012).","journal-title":"Science"},{"key":"1240_CR2","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1038\/onc.2010.154","volume":"29","author":"JL Dean","year":"2010","unstructured":"Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A. & Knudsen, E. S. Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 29, 4018\u20134032 (2010).","journal-title":"Oncogene"},{"key":"1240_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"1240_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/leu.2010.311","volume":"25","author":"C B\u00f6d\u00f6r","year":"2011","unstructured":"B\u00f6d\u00f6r, C. et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 25, 726\u2013729 (2011).","journal-title":"Leukemia"},{"key":"1240_CR5","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1158\/1535-7163.MCT-13-0876","volume":"13","author":"H Ott","year":"2014","unstructured":"Ott, H. et al. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation. Mol. Cancer Ther. 13, 3062\u20133073 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"1240_CR6","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1073\/pnas.1116418109","volume":"109","author":"MT McCabe","year":"2012","unstructured":"McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989\u20132994 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1240_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108 (2012).","journal-title":"Nature"},{"key":"1240_CR8","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C Bodor","year":"2013","unstructured":"Bodor, C. et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122, 3165\u20133168 (2013).","journal-title":"Blood"},{"key":"1240_CR9","doi-asserted-by":"crossref","unstructured":"Lunning, M. A. & Green, M. R. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 5, 1\u20137 (2015).","DOI":"10.1038\/bcj.2015.89"},{"key":"1240_CR10","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1016\/j.febslet.2012.07.066","volume":"586","author":"CR Majer","year":"2012","unstructured":"Majer, C. R. et al. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett. 586, 3448\u20133451 (2012).","journal-title":"FEBS Lett."},{"key":"1240_CR11","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1038\/sj.onc.1207749","volume":"23","author":"M Oeggerli","year":"2004","unstructured":"Oeggerli, M. et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23, 5616\u20135623 (2004).","journal-title":"Oncogene"},{"key":"1240_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000087804","volume":"75","author":"S Arisan","year":"2005","unstructured":"Arisan, S. et al. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol. Int. 75, 252\u2013257 (2005).","journal-title":"Urol. Int."},{"key":"1240_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1349-7006.2006.00203.x","volume":"97","author":"Y Matsukawa","year":"2006","unstructured":"Matsukawa, Y. et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 97, 484\u2013491 (2006).","journal-title":"Cancer Sci."},{"key":"1240_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624\u2013629 (2002).","journal-title":"Nature"},{"key":"1240_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann, I. M. et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268\u2013273 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1240_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4161\/epi.6.3.14056","volume":"6","author":"T Nguyen","year":"2011","unstructured":"Nguyen, T. et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6, 388\u2013394 (2011).","journal-title":"Epigenetics"},{"key":"1240_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","volume":"43","author":"ST Lee","year":"2011","unstructured":"Lee, S. T. et al. Context-specific regulation of NF-kappa B target gene expression by EZH2 in breast cancers. Mol. Cell 43, 798\u2013810 (2011).","journal-title":"Mol. Cell"},{"key":"1240_CR18","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1128\/MCB.00162-07","volume":"27","author":"B Shi","year":"2007","unstructured":"Shi, B. et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell. Biol. 27, 5105\u20135119 (2007).","journal-title":"Mol. Cell. Biol."},{"key":"1240_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","volume":"46","author":"H Yamaguchi","year":"2014","unstructured":"Yamaguchi, H. & Hung, M. C. Regulation and Role of EZH2 in Cancer. Cancer Res. Treat. 46, 209\u2013222 (2014).","journal-title":"Cancer Res. Treat."},{"key":"1240_CR20","doi-asserted-by":"crossref","unstructured":"Gan, L. et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark. Res. 6, 1\u201310 (2018).","DOI":"10.1186\/s40364-018-0122-2"},{"key":"1240_CR21","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1227604","volume":"338","author":"KX Xu","year":"2012","unstructured":"Xu, K. X. et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 338, 1465\u20131469 (2012).","journal-title":"Science"},{"key":"1240_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ajpath.2021.01.013","volume":"191","author":"T Anwar","year":"2021","unstructured":"Anwar, T., Gonzalez, M. E. & Kleer, C. G. Noncanonical functions of the polycomb group protein EZH2 in breast cancer. Am. J. Pathol. 191, 774\u2013783 (2021).","journal-title":"Am. J. Pathol."},{"key":"1240_CR23","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1073\/pnas.1308953111","volume":"111","author":"M Gonzalez","year":"2014","unstructured":"Gonzalez, M. et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc. Natl Acad. Sci. USA 111, 3098\u20133103 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1240_CR24","doi-asserted-by":"crossref","unstructured":"Anwar, T. et al. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. Nat. Commun. 9, 1\u201313 (2018).","DOI":"10.1038\/s41467-018-05078-8"},{"key":"1240_CR25","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3390\/ijms18091986","volume":"18","author":"Y-C Lee","year":"2017","unstructured":"Lee, Y.-C. et al. Hsp90\u03b1 mediates BMI1 expression in breast cancer stem\/progenitor cells through facilitating nuclear translocation of c-Myc and EZH2. Int. J. Mol. Sci. 18, 1986 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"1240_CR26","doi-asserted-by":"publisher","first-page":"e0165005","DOI":"10.1371\/journal.pone.0165005","volume":"11","author":"CL Lawrence","year":"2016","unstructured":"Lawrence, C. L. & Baldwin, A. S. Non-canonical EZH2 transcriptionally activates RelB in triple negative breast cancer. PLoS ONE 11, e0165005 (2016).","journal-title":"PLoS ONE"},{"key":"1240_CR27","doi-asserted-by":"publisher","first-page":"7922","DOI":"10.1073\/pnas.1303800110","volume":"110","author":"SK Knutson","year":"2013","unstructured":"Knutson, S. K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922\u20137927 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1240_CR28","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1021\/acs.jmedchem.6b01315","volume":"59","author":"RG Vaswani","year":"2016","unstructured":"Vaswani, R. G. et al. Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a potent and selective inhibitor of histone methyltransferase EZH2, suitable for phase I clinical trials for B-cell lymphomas. J. Med. Chem. 59, 9928\u20139941 (2016).","journal-title":"J. Med. Chem."},{"key":"1240_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1021\/cb400133j","volume":"8","author":"KD Konze","year":"2013","unstructured":"Konze, K. D. et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324\u20131334 (2013).","journal-title":"ACS Chem. Biol."},{"key":"1240_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nchembio.1084","volume":"8","author":"S Knutson","year":"2012","unstructured":"Knutson, S. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890\u2013896 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"1240_CR31","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","volume":"131","author":"M Bisserier","year":"2018","unstructured":"Bisserier, M. & Wajapeyee, N. Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood 131, 2125\u20132137 (2018).","journal-title":"Blood"},{"key":"1240_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/onc.2015.114","volume":"35","author":"V Gibaja","year":"2016","unstructured":"Gibaja, V. et al. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene 35, 558\u2013566 (2016).","journal-title":"Oncogene"},{"key":"1240_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","volume":"16","author":"AQ Ma","year":"2020","unstructured":"Ma, A. Q. et al. Discovery of a first-in-class EZH2 selective degrader. Nat. Chem. Biol. 16, 214 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1240_CR34","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","volume":"64","author":"ZH Liu","year":"2021","unstructured":"Liu, Z. H. et al. Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2. J. Med. Chem. 64, 2829\u20132848 (2021).","journal-title":"J. Med. Chem."},{"key":"1240_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0002-9440(10)65257-1","volume":"154","author":"HX An","year":"1999","unstructured":"An, H. X., Beckmann, M. W., Reifenberger, G., Bender, H. G. & Niederacher, D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol. 154, 113\u2013118 (1999).","journal-title":"Am. J. Pathol."},{"key":"1240_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4161\/cbt.3.3.698","volume":"3","author":"L Samady","year":"2004","unstructured":"Samady, L., Dennis, J., Budhram-Mahadeo, V. & Latchman, D. S. Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor. Cancer Biol. Ther. 3, 317\u2013323 (2004).","journal-title":"Cancer Biol. Ther."},{"key":"1240_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2005.12.012","volume":"9","author":"QY Yu","year":"2006","unstructured":"Yu, Q. Y. et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23\u201332 (2006).","journal-title":"Cancer Cell"},{"key":"1240_CR38","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","volume":"13","author":"C Sherr","year":"1999","unstructured":"Sherr, C. & Roberts, J. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501\u20131512 (1999).","journal-title":"Genes Dev."},{"key":"1240_CR39","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma, C. X. et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin. Cancer Res. 23, 4055\u20134065 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1240_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.18632\/genesandcancer.24","volume":"5","author":"A Witkiewicz","year":"2014","unstructured":"Witkiewicz, A., Cox, D. & Knudsen, E. CDK4\/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer 5, 261\u2013272 (2014).","journal-title":"Genes Cancer"},{"key":"1240_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","volume":"29","author":"S Goel","year":"2016","unstructured":"Goel, S. et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors. Cancer Cell 29, 255\u2013269 (2016).","journal-title":"Cancer Cell"},{"key":"1240_CR42","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","volume":"23","author":"US Asghar","year":"2017","unstructured":"Asghar, U. S. et al. Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer. Clin. Cancer Res. 23, 5561\u20135572 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1240_CR43","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Invest."},{"key":"1240_CR44","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1128\/MCB.19.10.7011","volume":"19","author":"T Tsutsui","year":"1999","unstructured":"Tsutsui, T. et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol. Cell. Biol. 19, 7011\u20137019 (1999).","journal-title":"Mol. Cell. Biol."},{"key":"1240_CR45","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M Alvarez-Fernandez","year":"2020","unstructured":"Alvarez-Fernandez, M. & Malumbres, M. Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell 37, 514\u2013529 (2020).","journal-title":"Cancer Cell"},{"key":"1240_CR46","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1039\/C9CC00163H","volume":"55","author":"BS Zhao","year":"2019","unstructured":"Zhao, B. S. & Burgess, K. PROTACs suppression of CDK4\/6, crucial kinases for cell cycle regulation in cancer. Chem. Commun. 55, 2704\u20132707 (2019).","journal-title":"Chem. Commun."},{"key":"1240_CR47","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1038\/onc.2008.333","volume":"27","author":"Q Cao","year":"2008","unstructured":"Cao, Q. et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27, 7274\u20137284 (2008).","journal-title":"Oncogene"},{"key":"1240_CR48","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1038\/sj.onc.1203336","volume":"18","author":"KM Hajra","year":"1999","unstructured":"Hajra, K. M., Ji, X. & Fearon, E. R. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 18, 7274\u20137279 (1999).","journal-title":"Oncogene"},{"key":"1240_CR49","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.15252\/embj.201694058","volume":"36","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. EMBO J. 36, 1243\u20131260 (2017).","journal-title":"EMBO J."},{"key":"1240_CR50","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761\u2013772 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"1240_CR51","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.4161\/auto.25190","volume":"9","author":"JV Ferreira","year":"2013","unstructured":"Ferreira, J. V. et al. STUB1\/CHIP is required for HIF1A degradation by chaperone-mediated autophagy. Autophagy 9, 1349\u20131366 (2013).","journal-title":"Autophagy"},{"key":"1240_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41594-018-0036-6","volume":"25","author":"JW H\u00f8jfeldt","year":"2018","unstructured":"H\u00f8jfeldt, J. W. et al. Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2. Nat. Struct. Mol. Biol. 25, 225\u2013232 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1240_CR53","doi-asserted-by":"crossref","unstructured":"Holoch, D. & Margueron, R. in Polycomb Group Proteins, 191\u2013224 (Elsevier, 2017).","DOI":"10.1016\/B978-0-12-809737-3.00009-X"},{"key":"1240_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386.e310 (2018).","journal-title":"Cell"},{"key":"1240_CR55","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/15592294.2019.1633867","volume":"14","author":"ST Kosalai","year":"2019","unstructured":"Kosalai, S. T. et al. EZH2 upregulates the PI3K\/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia. Epigenetics 14, 1125\u20131140 (2019).","journal-title":"Epigenetics"},{"key":"1240_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molcel.2013.08.028","volume":"52","author":"H Jung","year":"2013","unstructured":"Jung, H. et al. PAF and EZH2 induce Wnt\/\u03b2-catenin signaling hyperactivation. Mol. Cell 52, 193\u2013205 (2013).","journal-title":"Mol. Cell"},{"key":"1240_CR57","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1038\/onc.2016.453","volume":"36","author":"J Li","year":"2017","unstructured":"Li, J. et al. TRIM28 interacts with EZH2 and SWI\/SNF to activate genes that promote mammosphere formation. Oncogene 36, 2991\u20133001 (2017).","journal-title":"Oncogene"},{"key":"1240_CR58","doi-asserted-by":"crossref","unstructured":"Curry, E. et al. Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. Clin. Epigenetics 7, 1\u201312 (2015).","DOI":"10.1186\/s13148-015-0118-9"},{"key":"1240_CR59","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.celrep.2016.11.032","volume":"17","author":"A Collinson","year":"2016","unstructured":"Collinson, A. et al. Deletion of the polycomb-group protein EZH2 leads to compromised self-renewal and differentiation defects in human embryonic stem cells. Cell Rep. 17, 2700\u20132714 (2016).","journal-title":"Cell Rep."},{"key":"1240_CR60","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1038\/sj.emboj.7600402","volume":"23","author":"D Pasini","year":"2004","unstructured":"Pasini, D., Bracken, A. P., Jensen, M. R., Lazzerini Denchi, E. & Helin, K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 23, 4061\u20134071 (2004).","journal-title":"EMBO J."},{"key":"1240_CR61","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","volume":"32","author":"R Margueron","year":"2008","unstructured":"Margueron, R. et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503\u2013518 (2008).","journal-title":"Mol. Cell"},{"key":"1240_CR62","doi-asserted-by":"publisher","first-page":"8774","DOI":"10.1093\/nar\/gkv776","volume":"43","author":"KH Yoo","year":"2015","unstructured":"Yoo, K. H. et al. Loss of EZH2 results in precocious mammary gland development and activation of STAT5-dependent genes. Nucleic Acids Res. 43, 8774\u20138789 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1240_CR63","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","volume":"32","author":"X Shen","year":"2008","unstructured":"Shen, X. et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491\u2013502 (2008).","journal-title":"Mol. Cell"},{"key":"1240_CR64","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","volume":"30","author":"J Pascual","year":"2019","unstructured":"Pascual, J. & Turner, N. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann. Oncol. 30, 1051\u20131060 (2019).","journal-title":"Ann. Oncol."},{"key":"1240_CR65","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/jcc.23136","volume":"34","author":"X Ouyang","year":"2013","unstructured":"Ouyang, X. et al. CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. J. Comput. Chem. 34, 326\u2013336 (2013).","journal-title":"J. Comput. Chem."},{"key":"1240_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-020-2847-y","volume":"587","author":"BF Liu","year":"2020","unstructured":"Liu, B. F. et al. The landscape of RNA Pol II binding reveals a stepwise transition during ZGA. Nature 587, 139 (2020).","journal-title":"Nature"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01240-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01240-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01240-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T01:02:29Z","timestamp":1673830949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01240-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1038\/s41392-022-01240-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"7 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}